Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Developments examine found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://toddz974zfq3.verybigblog.com/profile